Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus

Published:2017 Issue:1 Volume:41 Page:69
ISSN:2233-6079
Container-title:Diabetes & Metabolism Journal
language:en
Short-container-title:Diabetes Metab J

Author:

Yoon Kun-Ho¹^ORCID,Hardy Elise²,Han Jenny³

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

2. AstraZeneca, Gaithersburg, MD, USA.

3. Pharmapace, San Diego, CA, USA.

Funder

AstraZeneca

Publisher

Korean Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism

Link

https://synapse.koreamed.org/pdf/10.4093/dmj.2017.41.1.69

Reference19 articles.

1. Diabetes in Asia

2. The Epidemiology of Diabetes in Korea

3. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

4. Prevalence, Awareness, and Management of Obesity in Korea: Data from the Korea National Health and Nutrition Examination Survey (1998-2011)

5. Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia;Advances in Therapy;2019-03-11

2. Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist;The Journal of Korean Diabetes;2019

3. Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta‐analysis involving eight eligible randomized‐controlled trials;Journal of Cellular Physiology;2018-08-26

4. Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association;The Journal of Korean Diabetes;2018

5. Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials;Scientific Reports;2017-11-22